Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
filingDate |
2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71fcb5e02903ebcf798b5a48f286b9cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14275e08e676db1413c7a920d7b80058 |
publicationDate |
2018-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
SI-2746404-T1 |
titleOfInvention |
ANTITUM AND THERAPEUTIC EFFECTS OF THE FORMAL METHOD FOR PATIENTS WITH KRAS-MUTRIC COLORECTAL CANCER |
abstract |
The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent that contains a,a,a-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl) uracil hydrochloride in a molar ratio of 1:0.5 in patients with colorectal cancer, the method comprising steps (1) and (2): (1) a step for detecting the presence or absence of mutation of the KRAS gene contained in a biological sample collected from the patient, and (2) a step for predicting a high likelihood that the chemotherapy will exhibit an adequate therapeutic effect in that patient, when the result confirmed in step (1) shows that the KRAS gene has mutated. |
priorityDate |
2011-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |